Tender number 1

Auto-translated from da

Original title: Udbudsnummer 1

Amgros I/S

Published: Oct 22, 2026

Updated: Oct 22, 2026

Source: TED - Tenders Electronic Daily (EU)

This tender has been awarded

Awarded to Abcur AB; Orifarm A/S; Abacus Medicine A/S — DKK 101,000,000

Browse open Health & Medical tenders in Denmark

About This Opportunity

This is a supplies contract in the health and medical services sector. Located in Denmark, Europe, this opportunity is open to firms and consortiums, with an estimated budget of DKK 8.7 million.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.

Description

Auto-translated from da

Tender number (sub-contract) includes the following medicines: ATC Code: N05AH03 · Generic name: Olanzapine · Dosage form: Depot injection · Strength: 210 mg · Unit value: 10 mg · Quantity in units: 22575. Each tender number is considered an independent sub-contract and is tendered independently of the other tender numbers. A supplier may therefore choose to bid on one, several, or all tender numbers, and awarding is done separately for each individual tender number. A supplier may thus be awarded one, several, or all sub-contracts. Reference is made to the tender conditions, including regarding submitting bids for the individual tender numbers. Under the heading "quantity in units" above, an estimated consumption of the medicines under the tender number is indicated, but the actual consumption may deviate significantly from it. Suppliers must take this into account. The reason for this is that these are medicines for patient treatment in public hospitals, where the patient's needs must be met. For a more detailed description, please refer to the tender conditions and the framework agreement.

Data provenance

This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on October 22, 2026. Last refreshed 4 days ago. Original language: da. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About Amgros I/S

Amgros I/S has issued 294 procurement notices on BidsFactory, including 11 currently open and 138 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Media & Communications. All notices are published for Denmark. Notices are distributed via TED - Tenders Electronic Daily (EU) and Denmark Udbud. Most recent publication: October 27, 2026.

Frequently asked questions about this tender

How can I submit a bid?

Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.

Is this tender still open?

No — the contract has already been awarded to Abcur AB; Orifarm A/S; Abacus Medicine A/S. The award notice is archived on BidsFactory for transparency and market intelligence.

Who is the contracting authority?

This notice was issued by Amgros I/S in Denmark. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

How much was the contract awarded for?

Abcur AB; Orifarm A/S; Abacus Medicine A/S was awarded the contract for DKK 101,000,000. The figure reflects the value disclosed by the contracting authority in the award notice.

Where will the contract be performed?

The contract is for delivery in Denmark. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.